Lymphoma Coalition publishes research on the experiences of patients and care partners based on learnings from the Global Patient Survey on Lymphomas and CLL (GPS) and other projects.
It is imperative the issues raised by patients and their care partners through the biennial survey, interviews, focus groups and other initiatives are conveyed to the medical and research communities to improve care moving forward.
[{"id":44305,"link":"https:\/\/lymphoma-stg.clarovantdigital.com\/incidence-and-impact-of-misdiagnosis-in-diffuse-large-b-cell-lymphoma-dlbcl-an-analysis-from-lymphoma-coalitions-2024-global-patient-survey-on-lymphomas-cll\/","name":"incidence-and-impact-of-misdiagnosis-in-diffuse-large-b-cell-lymphoma-dlbcl-an-analysis-from-lymphoma-coalitions-2024-global-patient-survey-on-lymphomas-cll","thumbnail":{"url":"https:\/\/lymphoma-stg.clarovantdigital.com\/wp-content\/uploads\/eha2026-EHA-5986-abstract_Page_1-1.jpg","alt":""},"title":"Incidence and Impact of Misdiagnosis in Diffuse Large B-Cell Lymphoma (DLBCL): An Analysis From Lymphoma Coalition's 2024 Global Patient Survey on Lymphomas & CLL","author":{"name":"lc_author","link":"https:\/\/lymphoma-stg.clarovantdigital.com\/author\/lc_author\/"},"date":"Jun 10, 2026","dateGMT":"2026-06-10 16:21:24","modifiedDate":"2026-06-12 20:40:35","modifiedDateGMT":"2026-06-12 20:40:35","commentCount":"0","commentStatus":"closed","categories":{"coma":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/global-patient-survey\/\" rel=\"category tag\">Global Patient Survey<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/\" rel=\"category tag\">Subtype-Specific<\/a>","space":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/global-patient-survey\/\" rel=\"category tag\">Global Patient Survey<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/\" rel=\"category tag\">Subtype-Specific<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":2,"sec":11},"status":"publish","excerpt":"Accepted for publication at the European Hematology Association (EHA) 2026 Congress, taking place from 11\u201314 June 2026 in Stockholm, Sweden.\n\nDiffuse large B-cell lymphoma (DLBCL) is an aggressive form of lymphoma where a correct and timely diagnosis is critical to improving outcomes. However, diagnosis can be challenging, as symptoms may overlap with other illnesses, increasing the risk of misdiagnosis and delays in accessing appropriate care.\n\nThis study, using data from Lymphoma Coalition\u2019s 2024 Global Patient Survey on Lymphomas & CLL, examined the incidence of misdiagnosis among people with lived experience of DLBCL and its impact on diagnostic delays and healthcare utilisation across five European countries: Belgium, Bulgaria, France, Italy, and the United Kingdom."},{"id":43364,"link":"https:\/\/lymphoma-stg.clarovantdigital.com\/variances-in-patient-experiences-with-shared-decision-making-by-treatment-in-patients-with-lbcl-analysis-of-lymphoma-coalitions-2024-global-patient-survey-on-lymphomas-and-cll\/","name":"variances-in-patient-experiences-with-shared-decision-making-by-treatment-in-patients-with-lbcl-analysis-of-lymphoma-coalitions-2024-global-patient-survey-on-lymphomas-and-cll","thumbnail":{"url":"https:\/\/lymphoma-stg.clarovantdigital.com\/wp-content\/uploads\/EBMT-2026-Annual-Meeting-Poster-FV.png","alt":""},"title":"Variances In Patient Experiences With Shared Decision-Making By Treatment In Patients With LBCL: Analysis Of Lymphoma Coalition's 2024 Global Patient Survey On Lymphomas And CLL","author":{"name":"lc_author","link":"https:\/\/lymphoma-stg.clarovantdigital.com\/author\/lc_author\/"},"date":"Mar 27, 2026","dateGMT":"2026-03-27 15:55:01","modifiedDate":"2026-05-13 17:32:42","modifiedDateGMT":"2026-05-13 17:32:42","commentCount":"0","commentStatus":"closed","categories":{"coma":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/commdecision-making\/shareddecision-making\/\" rel=\"category tag\">Shared Decision-Making<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/\" rel=\"category tag\">Subtype-Specific<\/a>","space":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/commdecision-making\/shareddecision-making\/\" rel=\"category tag\">Shared Decision-Making<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/\" rel=\"category tag\">Subtype-Specific<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":3,"sec":27},"status":"publish","excerpt":"Presented during the 52nd Annual Meeting of the EBMT, March 22\u201325, 2026 in Madrid, Spain.\n\nLarge B-cell lymphoma (LBCL) is an aggressive form of lymphoma where timely, effective treatment decisions are critical. For individuals with relapsed\/refractory or high-risk disease, therapies such as stem cell transplant (SCT) and CAR-T are often recommended. In this context, shared decision-making (SDM) plays a vital role in ensuring that treatment choices reflect patient preferences, values, and understanding. However, differences in patient experiences and levels of involvement in decision-making may vary depending on the treatment received, highlighting the need to better understand how SDM is implemented in clinical practice.\n\nAim\nThis study explored variations in patient experiences with shared decision-making among people with lived experience of LBCL, comparing those who received CAR-T therapy and stem cell transplant.\n\nObjective: Identify differences in patient involvement, communication with healthcare providers, and treatment preferences across therapy types, to inform strategies that strengthen patient-centred care and improve shared decision-making practices."},{"id":41524,"link":"https:\/\/lymphoma-stg.clarovantdigital.com\/evolving-patient-reported-value-of-treatment-attributes-in-follicular-lymphoma-insights-from-the-lymphoma-coalition-2024-global-patient-survey-on-lymphomas-and-cll\/","name":"evolving-patient-reported-value-of-treatment-attributes-in-follicular-lymphoma-insights-from-the-lymphoma-coalition-2024-global-patient-survey-on-lymphomas-and-cll","thumbnail":{"url":"https:\/\/lymphoma-stg.clarovantdigital.com\/wp-content\/uploads\/Evolving-Patient-Reported-Value-of-Treatment-Attributes-in-Follicular-Lymphoma-Insights-From-the-Lymphoma-Coalition-2024-GPS.png","alt":""},"title":"Evolving Patient-Reported Value of Treatment Attributes in Follicular Lymphoma: Insights from the Lymphoma Coalition 2024 Global Patient Survey on Lymphomas And CLL","author":{"name":"","link":"https:\/\/lymphoma-stg.clarovantdigital.com\/author\/firstname lastname\/"},"date":"Dec 9, 2025","dateGMT":"2025-12-09 17:02:55","modifiedDate":"2025-12-09 17:59:18","modifiedDateGMT":"2025-12-09 17:59:18","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/\" rel=\"category tag\">Subtype-Specific<\/a>","space":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/\" rel=\"category tag\">Subtype-Specific<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":3,"sec":7},"status":"publish","excerpt":"Presented during the ASH Annual Meeting on December 6 in Orlando, Florida.\nFollicular lymphoma (FL) is a chronic, incurable lymphoma marked by repeated cycles of treatment and remission. As individuals move through multiple lines of therapy, the cumulative burden of symptoms, side effects, and treatment demands can influence what they value most in their care. Understanding how these priorities shift is essential to ensure treatment decisions remain aligned with patient expectations and lived experience.\n\nAim\nThis study explored how people with lived experience of FL prioritise key treatment attributes across different stages of their disease.\n\nObjective: Identify how the importance of clinical outcomes, quality of life, and practical treatment considerations changes over time, offering insights to support more responsive, patient-centred care planning."},{"id":39534,"link":"https:\/\/lymphoma-stg.clarovantdigital.com\/impact-of-unaddressed-side-effects-on-patient-trust-in-cll-treatment-plans\/","name":"impact-of-unaddressed-side-effects-on-patient-trust-in-cll-treatment-plans","thumbnail":{"url":"https:\/\/lymphoma-stg.clarovantdigital.com\/wp-content\/uploads\/Abstract1.png","alt":""},"title":"Unaddressed Side-Effects and Confidence in Care Plans in Lymphoma\/CLL","author":{"name":"","link":"https:\/\/lymphoma-stg.clarovantdigital.com\/author\/firstname lastname\/"},"date":"Jun 15, 2025","dateGMT":"2025-06-15 18:50:00","modifiedDate":"2025-12-09 17:00:09","modifiedDateGMT":"2025-12-09 17:00:09","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/cll\/\" rel=\"category tag\">CLL<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/sideeffects\/\" rel=\"category tag\">Side Effects<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/\" rel=\"category tag\">Subtype-Specific<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/\" rel=\"category tag\">Treatment & Side Effects<\/a>","space":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/cll\/\" rel=\"category tag\">CLL<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/sideeffects\/\" rel=\"category tag\">Side Effects<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/\" rel=\"category tag\">Subtype-Specific<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/\" rel=\"category tag\">Treatment & Side Effects<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":2,"sec":56},"status":"publish","excerpt":"Presented during the EHA Congress on June 12-15 in Milan, Italy. Patients with lymphoma or CLL frequently experience side effects that affect their wellbeing. Managing these side effects is a crucial part of care. When left unaddressed, they can cause additional distress\u2014both physical and emotional. It is still unclear how this may affect a patient\u2019s confidence in their treatment plan.\n\nAim\nThis study examined whether patients with lymphoma or CLL who did not receive support for side effects were more likely to report low confidence in their treatment plan.\nObjective: Identify specific side effects most strongly linked to reduced confidence, providing insight into how better symptom management could improve patient experience."},{"id":39964,"link":"https:\/\/lymphoma-stg.clarovantdigital.com\/therapeutic-utilisation-trends-in-lymphoma-and-chronic-lymphocytic-leukaemia-analysis-of-the-2022-global-patient-survey\/","name":"therapeutic-utilisation-trends-in-lymphoma-and-chronic-lymphocytic-leukaemia-analysis-of-the-2022-global-patient-survey","thumbnail":{"url":"https:\/\/lymphoma-stg.clarovantdigital.com\/wp-content\/uploads\/Abstract12.png","alt":""},"title":"Therapeutic Utilisation in Lymphoma\/CLL - 2022 Global Patient Survey","author":{"name":"","link":"https:\/\/lymphoma-stg.clarovantdigital.com\/author\/firstname lastname\/"},"date":"Apr 17, 2024","dateGMT":"2024-04-17 17:02:00","modifiedDate":"2025-10-14 14:50:44","modifiedDateGMT":"2025-10-14 14:50:44","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/cll\/\" rel=\"category tag\">CLL<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/\" rel=\"category tag\">Subtype-Specific<\/a>","space":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/cll\/\" rel=\"category tag\">CLL<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/\" rel=\"category tag\">Subtype-Specific<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":3,"sec":21},"status":"publish","excerpt":"Presented during the 50th EBMT Annual Meeting\n\nfrom 14-17 April in Glasgow, Scotland. The utilisation of autologous haematopoietic stem cell transplant (ahSCT) is one of many therapeutic options for patients with lymphoma. A gap exists in the knowledge base for the utilisation of this treatment modality from a global and pan-subtype perspective. In this study, we sought to explore the use of ahSCT and other treatment regimens from a cross-sectional view in the context of lymphoma and chronic lymphocytic leukaemia (CLL)."},{"id":39971,"link":"https:\/\/lymphoma-stg.clarovantdigital.com\/predicting-treatment-related-fatigue-in-the-context-of-lymphoma-and-chronic-lymphocytic-leukemia\/","name":"predicting-treatment-related-fatigue-in-the-context-of-lymphoma-and-chronic-lymphocytic-leukemia","thumbnail":{"url":"https:\/\/lymphoma-stg.clarovantdigital.com\/wp-content\/uploads\/Abstract1-2.png","alt":""},"title":"Predicting Treatment Related Fatigue in Lymphoma\/CLL","author":{"name":"","link":"https:\/\/lymphoma-stg.clarovantdigital.com\/author\/firstname lastname\/"},"date":"Apr 7, 2024","dateGMT":"2024-04-07 17:08:00","modifiedDate":"2025-10-14 14:51:18","modifiedDateGMT":"2025-10-14 14:51:18","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/cll\/\" rel=\"category tag\">CLL<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/fatigue\/\" rel=\"category tag\">Fatigue<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/\" rel=\"category tag\">Subtype-Specific<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/\" rel=\"category tag\">Treatment & Side Effects<\/a>","space":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/cll\/\" rel=\"category tag\">CLL<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/fatigue\/\" rel=\"category tag\">Fatigue<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/\" rel=\"category tag\">Subtype-Specific<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/\" rel=\"category tag\">Treatment & Side Effects<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":2,"sec":44},"status":"publish","excerpt":"Presented on 5 -7 April 2024 in Orlando, Flordia.\n\nPresented at the NCCN Annual ConferenceCancer-related fatigue (CRF) is highly prevalent, significantly impacts patient well-being, and is a hugely under-reported and poorly understood phenomenon.\n\nThis study aimed to build a predictive model to help identify patients at risk for CRF based on routinely collected clinical information in the context of lymphoma and chronic lymphocytic leukemia (CLL)."},{"id":39992,"link":"https:\/\/lymphoma-stg.clarovantdigital.com\/an-examination-of-health-literacy-amongst-patients-with-chronic-lymphocytic-leukemia-a-study-from-the-2022-global-patient-survey\/","name":"an-examination-of-health-literacy-amongst-patients-with-chronic-lymphocytic-leukemia-a-study-from-the-2022-global-patient-survey","thumbnail":{"url":"https:\/\/lymphoma-stg.clarovantdigital.com\/wp-content\/uploads\/Health-Literacy-in-Chronic-Lymphocytic-Leukemia-2022-Global-Patient-Survey.png","alt":""},"title":"Health Literacy in Chronic Lymphocytic Leukemia - 2022 Global Patient Survey","author":{"name":"","link":"https:\/\/lymphoma-stg.clarovantdigital.com\/author\/firstname lastname\/"},"date":"Oct 9, 2023","dateGMT":"2023-10-09 17:28:00","modifiedDate":"2025-10-14 14:52:30","modifiedDateGMT":"2025-10-14 14:52:30","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/cll\/\" rel=\"category tag\">CLL<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/healthliteracy\/\" rel=\"category tag\">Health Literacy<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/\" rel=\"category tag\">Subtype-Specific<\/a>","space":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/cll\/\" rel=\"category tag\">CLL<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/healthliteracy\/\" rel=\"category tag\">Health Literacy<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/\" rel=\"category tag\">Subtype-Specific<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":3,"sec":52},"status":"publish","excerpt":"Presented at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 6-9 October 2023 held in Boston, MA. Lymphoma Coalition (LC) supports over 90 member organizations across 55 countries. LC\u2019s overarching vision is equity in lymphoma outcomes across borders. Health literacy is a key aspect of efficient and meaningful communication between patients and physicians.\n\nChronic lymphocytic leukemia (CLL) can have a disease course that spans ten years or longer. The length of this course allows patients to have the opportunity to engage in shared decision-making with their primary lymphoma care provider.\n\nThis study sought to quantify health literacy using nine key terms relevant to those with CLL and to examine if core survey demographics were predictors of poor health literacy."},{"id":40027,"link":"https:\/\/lymphoma-stg.clarovantdigital.com\/impact-of-ageing-on-the-survivorship-experiences-of-patients-with-hodgkin-lymphoma\/","name":"impact-of-ageing-on-the-survivorship-experiences-of-patients-with-hodgkin-lymphoma","thumbnail":{"url":"https:\/\/lymphoma-stg.clarovantdigital.com\/wp-content\/uploads\/2025-09-17-13_44_46-Greenshot.png","alt":""},"title":"Impact of Ageing on Survivorship in Hodgkin Lymphoma","author":{"name":"","link":"https:\/\/lymphoma-stg.clarovantdigital.com\/author\/firstname lastname\/"},"date":"Oct 24, 2022","dateGMT":"2022-10-24 17:54:00","modifiedDate":"2025-10-14 15:06:42","modifiedDateGMT":"2025-10-14 15:06:42","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/\" rel=\"category tag\">Access to Care<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/age\/\" rel=\"category tag\">Age<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/hodgkinlymphoma\/\" rel=\"category tag\">Hodgkin Lymphoma<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/\" rel=\"category tag\">Psychosocial & Quality of Life<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/qualityoflife\/\" rel=\"category tag\">Quality of Life<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/\" rel=\"category tag\">Subtype-Specific<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/survivorship\/\" rel=\"category tag\">Survivorship<\/a>","space":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/\" rel=\"category tag\">Access to Care<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/age\/\" rel=\"category tag\">Age<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/hodgkinlymphoma\/\" rel=\"category tag\">Hodgkin Lymphoma<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/\" rel=\"category tag\">Psychosocial & Quality of Life<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/qualityoflife\/\" rel=\"category tag\">Quality of Life<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/\" rel=\"category tag\">Subtype-Specific<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/survivorship\/\" rel=\"category tag\">Survivorship<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":3,"sec":23},"status":"publish","excerpt":"Presented at the the International Symposium on Hodgkin Lymphoma (ISHL12) in Cologne, Germany, from October 22-24. Hodgkin lymphoma (HL) often affects young adults and has one of the highest cure rates among all cancers, leading to an increasing number of survivors each year.\n\nIts treatment may cause long-term or late effects, which can impact a patient\u2019s overall health and quality of life. These effects raise concerns about survivorship care and long-term management.\n\nThis study uses data from the Lymphoma Coalition (LC) 2022 Global Patient Survey (GPS) on lymphoma and CLL to examine the survivorship experiences of HL patients in remission."},{"id":40034,"link":"https:\/\/lymphoma-stg.clarovantdigital.com\/psychosocial-experiences-in-relapsed-refractory-dlbcl-car-t-vs-other-therapies\/","name":"psychosocial-experiences-in-relapsed-refractory-dlbcl-car-t-vs-other-therapies","thumbnail":{"url":"https:\/\/lymphoma-stg.clarovantdigital.com\/wp-content\/uploads\/Abstract_96-Psychosocial-CART-vs-non-CART-1-1.png","alt":""},"title":"Psychosocial Experiences in Relapsed\/Refractory DLBCL: CAR-T vs. Other Therapies","author":{"name":"","link":"https:\/\/lymphoma-stg.clarovantdigital.com\/author\/firstname lastname\/"},"date":"Feb 11, 2022","dateGMT":"2022-02-11 18:02:00","modifiedDate":"2025-10-14 15:07:41","modifiedDateGMT":"2025-10-14 15:07:41","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/car-t-research\/\" rel=\"category tag\">CAR-T Research<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/psychosocial\/\" rel=\"category tag\">Psychosocial<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/\" rel=\"category tag\">Psychosocial & Quality of Life<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/relapserefractory\/\" rel=\"category tag\">Relapse\/Refractory<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/\" rel=\"category tag\">Subtype-Specific<\/a>","space":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/car-t-research\/\" rel=\"category tag\">CAR-T Research<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/psychosocial\/\" rel=\"category tag\">Psychosocial<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/\" rel=\"category tag\">Psychosocial & Quality of Life<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/relapserefractory\/\" rel=\"category tag\">Relapse\/Refractory<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/\" rel=\"category tag\">Subtype-Specific<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":2,"sec":41},"status":"publish","excerpt":"Presented during the \u201cBest Abstract Session\u201d at the 5th European CAR-T Cell Meeting in Rotterdam, The Netherlands, February 9-11. Chimeric antigen receptor T-cell (CAR-T) therapy continues to expand as a treatment option for patients with relapsed\/refractory diffuse large B cell lymphoma (DLBCL). This study provides insight into the psychosocial experiences of patients with relapsed and refractory DLBCL treated with CAR-T compared to other therapies."}]